India to United States: Adalimumab Export Trade Route

To import Adalimumab formulations into the United States, the following approvals and registrations are mandatory:

• Biologics License Application (BLA): Adalimumab, being a biological product, necessitates an approved BLA from the FDA.

• Establishment Registration and Drug Listing: Foreign manufacturers must register their facilities with the FDA and list all drug products intended for U.S. commercial distribution.

• Import Entry Filing: Importers are required to submit an entry notice and an entry bond to U.S. Customs and Border Protection (CBP) for each shipment.

• Electronic Submission: All submissions, including the BLA, should be in the electronic Common Technical Document (eCTD) format.

• Timelines and Fees: The FDA's review process for a BLA typically spans 10 months under the standard review process. Fees are subject to annual adjustments; for the fiscal year 2026, the BLA application fee is $3,117,218.

• GMP Inspection: The FDA mandates Good Manufacturing Practice (GMP) inspections of foreign manufacturing facilities to ensure compliance with U.S. standards. These inspections are a prerequisite for BLA approval and subsequent importation.

Indian manufacturers exporting Adalimumab formulations to the United States must comply with the following GMP standards:

• FDA GMP Compliance: Facilities must adhere to the FDA's GMP regulations, ensuring products meet quality and safety standards.

• Facility Approval: Only facilities that have undergone and passed FDA inspections are authorized to export to the U.S. As of March 2026, specific details on approved Indian facilities are not publicly disclosed.

• Recent Inspections and Actions: The FDA conducts regular inspections of Indian pharmaceutical facilities. In December 2025, the FDA issued a warning letter to an Indian manufacturer for GMP violations, highlighting the agency's ongoing vigilance.

Several regulatory changes between 2024 and 2026 have impacted Indian pharmaceutical exports to the United States:

• Mutual Recognition Agreement (MRA): In July 2024, the FDA and India's Central Drugs Standard Control Organization (CDSCO) signed an MRA, facilitating mutual recognition of GMP inspections. This agreement aims to streamline the inspection process and reduce regulatory burdens.

• Updated Guidance on Biosimilars: In January 2025, the FDA released updated guidance on biosimilar product development, emphasizing the need for comprehensive analytical studies and clinical trials. This guidance affects Adalimumab biosimilars seeking U.S. market entry.

• Enhanced Import Surveillance: In September 2025, the FDA implemented an enhanced import surveillance program, increasing scrutiny of pharmaceutical imports from India. This initiative aims to ensure compliance with U.S. quality standards and protect public health.

Indian exporters must stay informed about these developments to maintain compliance and ensure uninterrupted access to the U.S. market.

In 2024, the U.S. market for Adalimumab formulations, primarily branded as Humira, was valued at approximately $10.34 billion. Projections indicate a decline to $4.11 billion by 2030, reflecting a compound annual growth rate (CAGR) of -11.29% from 2025 to 2030. This downturn is largely due to the introduction of biosimilars following patent expirations. Despite the market's contraction, the prevalence of autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease continues to drive demand for Adalimumab formulations. In 2023, a study estimated that autoimmune diseases affect approximately one in ten individuals globally. The U.S. market is predominantly supplied by domestic manufacturers, with imports playing a supplementary role.

The United States maintains a 0% Most-Favored-Nation (MFN) import duty rate for pharmaceutical products classified under HS code 30021500, which includes finished formulations containing Adalimumab. There are no additional import duties, Value Added Tax (VAT), or Goods and Services Tax (GST) imposed on these pharmaceutical imports. Currently, there is no Free Trade Agreement (FTA) between India and the United States that specifically affects pharmaceutical tariffs. Additionally, there are no anti-dumping duties imposed on Adalimumab formulations imported into the United States.

The United States sources Adalimumab formulations from several countries, with Germany being a notable supplier. For instance, in May and June 2024, multiple shipments of pharmaceuticals under HS code 30021500 were imported from Germany through the port of Charleston, South Carolina. India's contribution to the U.S. Adalimumab import market is minimal, accounting for only 0.1% of India's total Adalimumab formulation exports, valued at $1.2 million. Specific data on India's pricing compared to competitors like China and European Union manufacturers is not readily available. However, the introduction of biosimilars has generally led to increased price competition in the market.

India is a global leader in generic pharmaceutical production, accounting for approximately 20% of the global supply by volume. The country has a robust infrastructure for manufacturing finished dosage forms, including formulations containing Adalimumab. As of November 2024, India had 134 FDA-registered facilities dedicated to finished dosage forms, underscoring its significant manufacturing capacity. This extensive network of WHO-GMP and FDA-approved facilities ensures adherence to stringent quality standards, making India a preferred source for Adalimumab formulations. Additionally, India's cost-effective production processes offer competitive pricing advantages for various dosage forms, including tablets, capsules, and injections.

When comparing Adalimumab formulation exports, India offers a compelling balance of cost and quality. In the United States, the average pharmacy acquisition cost for Adalimumab biosimilars was approximately $1,593 per milliliter as of February 2026. In contrast, biosimilars in China were priced at about 82% of the reference drug's cost, reflecting a moderate discount. European biosimilars have achieved price reductions of 50–80% compared to originator products. (cdn.who.int) Indian manufacturers are known for their stringent adherence to international quality standards, with numerous facilities holding FDA and WHO-GMP certifications. This compliance ensures regulatory acceptance in the United States and a reliable supply chain.

India's pharmaceutical industry demonstrates strong supply reliability for Adalimumab formulations. The country maintains a substantial number of FDA-registered facilities, with 134 dedicated to finished dosage forms as of November 2024. These facilities are equipped with advanced packaging and cold chain capabilities essential for biologic formulations. While specific data on recent supply disruptions are limited, India's consistent regulatory compliance and ongoing facility expansions suggest a stable supply chain. Manufacturers continue to invest in capacity enhancements to meet growing global demand.

For U.S. buyers sourcing Adalimumab formulations from India, consider the following strategies:

• Dual-Sourcing Strategy: Engage multiple Indian suppliers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary; negotiate terms that align with your demand forecasts to optimize inventory levels.

• Payment Terms: Standard payment terms in India-U.S. pharmaceutical trade often include letters of credit or advance payments; establish clear terms to maintain financial clarity.

• Supplier Qualification Process: Conduct thorough due diligence, including audits of manufacturing facilities, verification of regulatory certifications, and assessment of quality control systems to ensure compliance with U.S. standards.

• Regulatory Compliance: Ensure that selected suppliers have a strong track record of FDA compliance to facilitate smooth importation and market entry.

Implementing these recommendations will enhance the reliability and efficiency of sourcing Adalimumab formulations from India.

By meticulously following these guidelines, United States companies can effectively qualify Indian suppliers of Adalimumab formulations, ensuring compliance with regulatory standards and safeguarding product quality.